CUE-200

CUE-200 is a **preclinical Immuno-STAT biologic framework** from Cue Biopharma rather than a single fully disclosed named clinical candidate. Within the company's platform, the CUE-200 series is described as an injectable Fc-fusion biologic designed to present an antigenic peptide-MHC class I signal together with **co-stimulatory ligands such as CD80 and or 4-1BBL** to selectively engage disease-relevant T cells. The intended mechanism is to **reactivate exhausted antigen-specific T cells** and enhance their expansion and function, with early positioning especially in **chronic infectious disease** and related immune-restorative applications. Public information indicates that this is a platform or series-level program and not a marketed product, with limited molecule-specific disclosure on exact construct, indication, formulation, manufacturing details, or clinical-stage development for the exact name CUE-200.

Other names

CUE-200 seriesCUE200 seriesCUE 200 series